Perinatal EvidenceCompass
Prepopulated workbenchMED-206

Insomnia — antihistamine/legacy sedative

Diphenhydramine

Sedating antihistamine, barbiturate, or legacy hypnotic

Not a categorical safety rating

This record organizes questions; it does not close them.

The clinical fields and position statements are prepopulated from the public-source corpus. They have not completed individual dual extraction, formal appraisal, exact-label reconciliation, or multidisciplinary sign-off. Do not use this page to justify abrupt discontinuation or reflexive switching.

Inventory identity

What this record represents

Canonical generic name
Diphenhydramine
Entity type
single-ingredient drug
Active component(s)
Diphenhydramine
Formulation / route / interval
Oral; formulation varies
Attachment entry
Diphenhydramine
Separate monograph status
No — cross-reference shared molecule monograph
Identity and cross-reference
Also: EPS, emergency agitation adjunct, and insomnia
Inventory verification confidence
Moderate — molecule-level source; exact product/jurisdiction pending

Decision taxonomy

Five positions kept separate

These are workbench statements for reviewer execution. They are not independently commissioned, patient-specific recommendations.

  1. 01

    Stable continuation

    Workbench statement

    Do not withhold or discontinue solely because of pregnancy or lactation. For this record, assess indication, prior response, relapse severity, dose/formulation, alternatives, exposure timing, and mapped evidence; individual commissioned adjudication remains pending.

  2. 02

    New initiation in pregnancy

    Workbench statement

    For a new start, prefer an effective option with the strongest diagnosis-specific efficacy and reproductive evidence when clinically suitable. This record has not received an individual, independently verified initiation ranking.

  3. 03

    Switch before conception

    Workbench statement

    Before conception, consider a switch only when expected benefit exceeds relapse, withdrawal, failed-switch, and dual-exposure risks. Build and monitor the plan before pregnancy when feasible; no universal switch direction is assigned here.

  4. 04

    Unplanned exposure

    Workbench statement

    After unplanned exposure, confirm product, route, dose, timing, indication, co-exposures, and symptoms; do not advise abrupt cessation. Use the mapped evidence and current label to decide whether any targeted fetal assessment is indicated.

  5. 05

    Delivery, postpartum & lactation

    Workbench statement

    Create separate delivery, postpartum-dose, neonatal-observation, and lactation plans. Do not infer breastfeeding suitability from pregnancy evidence or routinely taper before delivery without drug-specific support.

Linked evidence

3 mapped claim summaries

Mapping can include class-wide, framework, formulation, regulatory, or evidence-gap claims. A linked claim is not necessarily a drug-specific causal estimate.

A-044Provisional public source

Intermittent diphenhydramine, doxylamine, or promethazine exposure has not established a major-malformation pattern, but chronic use adds anticholinergic, tolerance, sedation, delivery, infant-sedation, and possible milk-supply concerns.

Public-source certainty descriptor
low-to-moderate for no large malformation effect; not GRADE
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
pregnancy, delivery, and lactation
Comparator
exposed versus background
Effect or numbers carried forward

No reliable quantitative estimate.

Limitations

Evidence often comes from antiemetic/allergy use rather than chronic insomnia; product and dose vary.

Sources, citation controls, and verification state

Linked sources

PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-067Provisional public source

FDA prescription labeling uses narrative Pregnancy and Lactation Labeling Rule sections rather than the former A/B/C/D/X letter categories.

Public-source certainty descriptor
high for US regulatory framework
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
pregnancy and lactation
Comparator
not applicable
Effect or numbers carried forward

No reliable quantitative estimate.

Limitations

Exact labeling and revision date remain product-specific; non-US systems differ.

Sources, citation controls, and verification state

Linked sources

PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-076Provisional public source

Diphenhydramine injection shares the active-moiety pregnancy/lactation profile of oral diphenhydramine, while parenteral use adds rapid anticholinergic and sedative effects; necessary acute allergy or extrapyramidal-symptom treatment should not be withheld solely because of pregnancy.

Public-source certainty descriptor
low-to-moderate for no large active-moiety malformation effect; insufficient route-specific evidence; not GRADE
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
acute pregnancy treatment, delivery, and lactation
Comparator
parenteral versus oral exposure; no reproductive comparator
Effect or numbers carried forward

No reliable reproductive effect estimate for the injection route.

Limitations

Indication, dose, co-sedatives, and rapid administration affect maternal risk; route-specific fetal and infant outcome cohorts are absent.

Sources, citation controls, and verification state

Linked sources

PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending